A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.
That is the results of a research involving the Università Cattolica del Sacro Cuore, Rome campus—Fondazione Policlinico Universitario Agostino Gemelli IRCCS, coordinated by Universitat Politècnica de Catalunya (UPC), Catalonia, Youngsters’s Emergency Division, Leicester Royal Infirmary and College of Edinburgh, the primary to investigate a “actual world” case research.
Developed to forestall respiratory syncytial virus infections, the drug has been authorized on the European degree to guard infants of their first season of publicity to the virus.
The work was printed in The Lancet Regional Well being—Europe journal and was coordinated by Dr. Danilo Buonsenso, researcher in Basic and Specialist Pediatrics on the College of Drugs of the Catholic College and pediatrician on the Pediatric Infectious Ailments Unit of the Fondazione Policlinico Gemelli IRCCS.
Buonsenso explains, “Now, for the primary time, a real-world research has analyzed the concrete impression of nirsevimab by evaluating European international locations with completely different well being insurance policies: Catalonia (Spain), the place the drug was launched in 2023-2024, and a few areas of the UK and Rome (Italy), the place it had not but been adopted.”
Bronchiolitis is an acute viral an infection that impacts the respiratory system of kids underneath one 12 months of age primarily within the first six months of life with larger frequency between November and March. It’s usually related to respiratory syncytial virus an infection (in about three out of 4 circumstances) that may trigger respiratory failure, particularly in youngsters underneath one 12 months of age and amongst infants underneath six months outdated.
However different viruses may also be the trigger: metapneumovirus, coronavirus, rhinovirus, adenovirus, influenza and parainfluenza viruses. An infection outcomes from transmission primarily by direct contact with contaminated secretions.
The info, collected from 68 Catalan hospitals and 5 hospitals in the UK and Italy, present a transparent end result: in youngsters underneath 6 months in Catalonia, hospitalizations for bronchiolitis have virtually halved in comparison with the typical of earlier seasons.
Emergency room admissions for a similar age group had been additionally considerably diminished. In distinction, no important discount emerged within the different European facilities the place nirsevimab was not administered.
The drug’s impact was much less pronounced in older youngsters (between 6 and 23 months), suggesting that the best efficacy is concentrated within the first few months of life. The authors additionally emphasize the necessity for bigger, internationally coordinated research, not least to evaluate the financial sustainability of introducing nirsevimab on a big scale.
The research represents an vital step in assessing the actual effectiveness of recent preventive methods in opposition to RSV, evaluating, for the primary time, international locations with completely different approaches to its implementation, Buonsenso concludes.
Extra info:
Actual-world impression of nirsevimab immunisation in opposition to respiratory illness on emergency division attendances and admissions amongst infants: a multinational retrospective evaluation, The Lancet Regional Well being – Europe (2025).
Quotation:
Bronchiolitis: Monoclonal antibody halves hospitalizations of kids youthful than 6 months outdated (2025, June 3)
retrieved 3 June 2025
from https://medicalxpress.com/information/2025-06-bronchiolitis-monoclonal-antibody-halves-hospitalizations.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
